The D-hormone analog alfacalcidol: The pioneer beyond the horizon of osteoporosis treatment

Journal of Rheumatology

Volumn 32, Issue SUPPL. 76, 2005, Pages 4-10

  Orimo, Hajime ^a   Schacht, Erich ^b  

^a Science University   (Japan)

^b BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Aged; D hormone analogs; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; COLECALCIFEROL DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; 1-HYDROXYCHOLECALCIFEROL; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; HYDROXYCOLECALCIFEROL; PRODRUG; VITAMIN;

AGING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; FALLING; FRACTURE; HUMAN; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; SECONDARY OSTEOPOROSIS; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANIMAL; ARTICLE; BONE REMODELING; DRUG EFFECT; FEMALE; HISTORY; JAPAN; MALE; PHYSIOLOGY; SKELETAL MUSCLE;

ACCIDENTAL FALLS; AGING; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CLINICAL TRIALS; FEMALE; FRACTURES, BONE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; MALE; MUSCLE, SKELETAL; OSTEOPOROSIS; PRODRUGS; VITAMIN D; VITAMINS;

EID: 24944548212     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Bischoff HA, Stähelin HB, Dick W. Effects of vitamin D and calcium supplementation on falls: a randomised controlled trial. J Bone Miner Res 2003;18:343-51.
2. Gallagher JC, Fowler SE, Detter JR, et al. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001;86:3618-28.
3. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-8.
4. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000;12:455-60.
5. Shiraki M, Orimo H, Ito H, et al. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol and 1,24-dihydroxycholecalciferol. Endocrinol Jpn 1985;32:305-15.
6. Orimo H, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha-vitamin D3. Bone Miner 1987;3:47-52.
7. Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6.
8. McCollum EV, Simmonds N, Becker JE, Shipley PG. Studies on experimental rickets. XXI. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922;53:293-312.
9. Windaus A, Lüttringhaus A. Über die Zahl der Kohlenstoffatome im Molekül der Sterine, vor allem des Ergosterins. Nachr Ces Wiss Goettingen, Math Phys Kl 1932;4.
10. Windaus A, Schenck F, von Werder T. Über das antirachitisch wirksame Bestrahlungsprodukt aus 7-Dehydro-Cholesterin. Hoppe-Seyler's Z Physiol Chem 1936;41:100.
11. Blunt JW, DeLuca HF, Schnoes HK. 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 1968;7:3317-22.
12. Lawson DE, Fraser DR, Kodicek E, Morris HR, Williams DH. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971;230:228-30.
13. Holick MF, Schnoes HK, DeLuca HF. Identification of 1,25- dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci USA 1971;68:803-4.
14. Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V. Popjak G. 1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine. Science 1971;173:51-4.
15. Ueno K, Okamiya Y, Makita T, Kurozumi S, Kawashima H, Hashimoto Y. Studies on biopharmacological activity of active vitamin D3 analogues (VII) Effect of 1 alpha-hydroxycholecalciferol on renal function in rats and Beagle dogs [Japanese]. Nippon Yakurigaku Zasshi 1979;75:617-31.
16. Inoue T, Kushida K. Diagnosis of metabolic bone diseases: radiographic diagnosis [Japanese], Nippon Rinsho 1986;44:2443-51.
17. Hayashi Y, Fujita T, Inoue T. Decrease of vertebral fractures in osteoporosis by administration of 1-alpha-hydroxyvitamin D3. J Bone Miner Metab 1992;10:50-4.
18. Tanizawa T, Imura K, Ishii Y, et al. Treatment with active vitamin D metabolites and concurrent treatment in the prevention of hip fractures; a retrospective study. Osteoporosis Int 1999;9:163-70.
19. Shiraki M, Ho H, Orimo H. The ultra-long term treatment of senile osteoporosis with 1-alpha-hydroxyvitamin D3. Bone Miner 1993;20:223-34.
20. Orimo H. Clinical application of 1 alpha (OH)D3 in Japan. Akt Rheumatol 1994;19:27.
21. Fujita T. Studies of osteoporosis in Japan. Metabolism 1990;39(4 Suppl 1):39-42.
22. Consensus Development Conference: Prophylaxis and Treatment of Osteoporosis. Am J Med 1991;90:107-10.
23. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of post-menopausal osteoporosis with calcitriol or calcium. New Engl J Med 1992;326:357-62.
24. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
25. World Congress on Osteoporosis, Amsterdam, The Netherlands, May 1996. Satellite symposium on new aspects in therapy with active vitamin D derivatives. Calcif Tissue Int 1997;60:100-33.
26. IOF World Congress on Osteoporosis, Berlin, Germany, September 1998. Satellite symposium on alfacalcidol - new aspects of a physiological anti-osteoporotic therapy. Calcif Tissue Int 1999;65:292-343.
27. IOF World Congress on Osteoporosis, Chicago, Illinois, USA, June 2000. Satellite symposium on aspects of alfacalcidol and D-hormone analogs. Osteoporos Int 2000;11:Suppl 2.
28. IOF World Congress on Osteoporosis, Lisbon, Portugal, May 2002. Satellite symposium on new findings on the effects of alfacalcidol and D-hormone analogs on fractures. Osteoporos Int 2002;13:Suppl.
29. IOF World Congress on Osteoporosis, Rio de Janeiro, Brazil, May 2004. Satellite symposium on glucocorticoid/inflammation-induced osteoporosis - pleiotropic effects of D-hormone analogs. Osteoporos Int 2004;15:Suppl.
30. Papadimitropoulos E, Wells G, Shea B, et al. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Rev 2002;23:560-9.
31. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocrine Rev 2002;23:570-8.
32. Richy F, Ethgen O, Bruyere O, Reginster J-Y. Efficacy of alpha-calcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15:301-10.
33. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
34. Harris S, Watts N, Genant H, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
35. Ettinger B, Black D, Mitlak B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
36. Ringe JD, Schacht E. Prevention and therapy of osteoporosis: The respective roles of plain vitamin D and alfacalcidol. Rheumatol Int 2004;24:189-97.
37. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999;65:317-27.
38. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81.
39. Lakatos P, Nagy Z, Kiss L, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000;59 Suppl 1:148-52.
40. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow up. J Rheumatol 1996;23:995-1000.
41. Shane E, Addesso V, Namerow P, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004;350:767-76.
42. de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602.
43. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004;24:63-70.
44. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 2001;33:19-24.
45. Boland R. Role of vitamin D in skeletal muscle function. Endocrine Rev 1986;784:434-48.
46. Endo I, Inoue D, Mitsui T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003;144:5138-44.
47. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004;19:265-9.
48. Bischoff HA, Stähelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999;80:54-8.
49. Dukas L, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J Nutrition Health Aging 2005. Published online.
50. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004;89-90:497-501.
51. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004;52:230-6.
52. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls. A meta-analysis. JAMA 2004;291:1999-2006.
53. DeLuca HF. Vitamin D metabolism. Clin Endocrinol 1977;7 Suppl:1S-17S.
54. 1 results from ligand-induced stabilization. J Biol Chem 1992;267:20082-6.
55. Miya K, Morimoto S, Fukuo K, et al. Cognitive function and calcium related factors in elderly female subjects. Nippon Ronen Igakkai Zasshi 1991;28:34-9.